Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(4-(1-((e)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl)-2-ethylbenzyl)-azetidine-3-carboxylic Acid
2. Baf-312
3. Baf312
4. Mayzent
5. Siponimod
1. Siponimod Hemifumarate
2. Nvp-baf312-aea
3. 1234627-85-0
4. Siponimod Fumaric Acid
5. Siponimod Hemifumaric Acid
6. Z7g02xz0m6
7. Siponimod Fumarate (usan)
8. Siponimod Fumarate [usan]
9. Siponimod Fumaric Acid (jan)
10. Siponimod Fumaric Acid [jan]
11. Baf-312
12. 3-azetidinecarboxylic Acid, 1-((4-((1e)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-, (2e)-2-butenedioate (2:1)
13. Mayzent (tn)
14. Unii-z7g02xz0m6
15. Chembl4298150
16. Ex-a4633
17. Siponimod Fumarate [who-dd]
18. Siponimod Fumarate [orange Book]
19. Siponimod Fumaric Acid [orange Book]
20. D11072
21. (e)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic Acid Compound With Fumaric Acid (2:1)
22. (e)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylicacidcompoundwithfumaricacid(2:1)
23. Bis-(1-((4-((1e)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)azetidine-3-carboxylic Acid) (2e)-but-2-enedioate
Molecular Weight | 1149.3 g/mol |
---|---|
Molecular Formula | C62H74F6N4O10 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 20 |
Exact Mass | 1148.53091354 g/mol |
Monoisotopic Mass | 1148.53091354 g/mol |
Topological Polar Surface Area | 199 Ų |
Heavy Atom Count | 82 |
Formal Charge | 0 |
Complexity | 896 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Sphingosine 1 Phosphate Receptor Modulators
Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS. (See all compounds classified as Sphingosine 1 Phosphate Receptor Modulators.)
L04
GDUFA
DMF Review : Complete
Rev. Date : 2022-12-16
Pay. Date : 2022-11-15
DMF Number : 37679
Submission : 2022-11-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-12-22
Pay. Date : 2022-11-10
DMF Number : 36596
Submission : 2021-12-09
Status : Active
Type : II
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?